Figure 4.

Additional secondary “no harm” end points according to initial treatment with lower-dose or higher-dose prednisone. (A) Cumulative incidence of non-relapse mortality among all patients, (B) among those in cohort A, and (C) among those in cohort B after initiation of prednisone therapy. (D) Cumulative incidence of relapse and (E) chronic GvHD requiring systemic immunosuppressive therapy among all patients after initiation of prednisone therapy. Solid line: patients who started treatment with lower-dose prednisone (0.5 mg/kg/day or 1 mg/kg/day for those in cohorts A and B, respectively). Dashed line: patients who started treatment with higher-dose prednisone (1 mg/kg/day or 2 mg/kg/day for those in cohorts A and B, respectively).